G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...

Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring orthopedic ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

ABC News' Dr. Tara Narula breaks down the FDA's decision to stop the making of compound versions of weight loss medications.

Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...